Abstract
MicroRNAs are a class of evolutionarily small non-coding RNAs of 19 to 25 nucleotides in length, that represent one of the most exciting areas of current medical science as they can regulate a complex regulatory network of gene expression and physiologic processes including differentiation, proliferation and apoptosis in a highly context dependent fashion. Recently, their role in cardiovascular disease and in the regulation of cardiomyocyte size and function, in the action potential, in angiogenesis and in mitochondrial function was recognized. Importantly, they have been evaluated for their prognostic and diagnostic role in heart failure and modification of specific microRNAs levels has been tested as a therapeutic option in experimental heart failure models. In this review article we refer the most emerging evidence, concerning the role of microRNAs in myocardial development in heart failure pathophysiology and prognosis, and their therapeutic implications.
Keywords: Biomarkers, heart failure, microRNA, myocardial hypertrophy, prognosis, treatment.
Current Topics in Medicinal Chemistry
Title:Diagnostic and Therapeutic Potentials of microRNAs in Heart Failure
Volume: 13 Issue: 13
Author(s): Evangelos Oikonomou, Gerasimos Siasos, Dimitris Tousoulis, Eleni Kokkou, Vasiliki Genimata, Konstantinos Zisimos, George Latsios and Christodoulos Stefanadis
Affiliation:
Keywords: Biomarkers, heart failure, microRNA, myocardial hypertrophy, prognosis, treatment.
Abstract: MicroRNAs are a class of evolutionarily small non-coding RNAs of 19 to 25 nucleotides in length, that represent one of the most exciting areas of current medical science as they can regulate a complex regulatory network of gene expression and physiologic processes including differentiation, proliferation and apoptosis in a highly context dependent fashion. Recently, their role in cardiovascular disease and in the regulation of cardiomyocyte size and function, in the action potential, in angiogenesis and in mitochondrial function was recognized. Importantly, they have been evaluated for their prognostic and diagnostic role in heart failure and modification of specific microRNAs levels has been tested as a therapeutic option in experimental heart failure models. In this review article we refer the most emerging evidence, concerning the role of microRNAs in myocardial development in heart failure pathophysiology and prognosis, and their therapeutic implications.
Export Options
About this article
Cite this article as:
Oikonomou Evangelos, Siasos Gerasimos, Tousoulis Dimitris, Kokkou Eleni, Genimata Vasiliki, Zisimos Konstantinos, Latsios George and Stefanadis Christodoulos, Diagnostic and Therapeutic Potentials of microRNAs in Heart Failure, Current Topics in Medicinal Chemistry 2013; 13 (13) . https://dx.doi.org/10.2174/15680266113139990104
DOI https://dx.doi.org/10.2174/15680266113139990104 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Initiation of Dialysis: A Mini-Review of a Changing Paradigm
Cardiovascular & Hematological Disorders-Drug Targets Heart Failure and Diabetes: Perspective of a Dangerous Association
Current Hypertension Reviews Patent Selections
Recent Patents on Cardiovascular Drug Discovery Advanced Strategies in the Diagnosis and Treatment of Patients with Coronary Artery Disease and Heart Failure: When Heart Failure Causes Ischemia and Angiotensin Converting Enzyme Inhibitor and Betablockers Helps in Diuresis
Current Pharmaceutical Design Synthesis and Electronic Properties of Phenothiazinyl Primary Amines
Letters in Organic Chemistry Epigenetics in Ocular Diseases
Current Genomics Advancements in Treatment Options of Women Infertility
Current Women`s Health Reviews Relationship Between Na<sup>+</sup>, K<sup>+</sup>-ATPase and NMDA Receptor at Central Synapses
Current Protein & Peptide Science Editorial (Thematic Issue: The Coronary Collateral Circulation – Past, Present and Future)
Current Cardiology Reviews PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets Pharmacogenomics and Sepsis-Induced Renal Failure: Effects of β 2-Adrenoceptor Function on the Course of Sepsis
Current Pharmacogenomics and Personalized Medicine Diabetic Cardiomyopathy: Clinical and Metabolic Approach
Current Vascular Pharmacology Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders Hyperglycaemia and Vitamin D: A Systematic Overview
Current Diabetes Reviews Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism Development of a Radiolabeled Amlodipine Analog for L-type Calcium Channel Imaging
Current Radiopharmaceuticals Should Percutaneous Coronary Intervention be the Standard Treatment Strategy for Significant Coronary Artery Disease in all Octogenarians?
Current Cardiology Reviews The Effects of Prostaglandin E-1 in Patients with Intermittent Claudication
Cardiovascular & Hematological Disorders-Drug Targets An insight into the Interaction between Clopidogrel and Proton Pump Inhibitors
Current Drug Metabolism Non-transfusion Dependent Thalassemias: A Developing Country Perspective
Current Pediatric Reviews